Efficacy and Safety of Botulinum Toxin A and Pulsed Radiofrequency on Postherpetic Neuralgia: A Randomized Clinical Trial

Table 1

Baseline information of the two groups of patients.

	RF	BoNT-A	t/X^2/Z
Gender (male/female)	26/24	26/24	0	1
Age (Years)	72.28 ± 7.43	72.20 ± 6.57	0.057	0.955
Course	1(1–2)	1(1–2)	−0.110	0.912
NRS	6.00 ± 1.01	6.12 ± 1.10	−0.568	0.166
ID-pain	3(2–3.25)	3(3–4)	−0.828	0.408
ST (without/with)	11/39	12/38	0.056	0.812
BU (without/with)	23/27	21/29	0.162	0.687
NU (without/with)	33/17	25/25	2.627	0.105
EL (without/with)	16/34	18/32	0.178	0.673
AL (without/with)	20/30	20/30	0	1
SP (without/with)	24/26	24/26	0	1
SQS	8.70 ± 2.56	8.88 ± 2.65	−0.346	0.730
GAD-7	9.82 ± 3.96	10.24 ± 4.27	−5.10	0.611
PHQ-9	11.62 ± 4.24	12.28 ± 4.24	−0.778	0.439

The course of PHN was divided into 4 stages: 1 = ≤3 months, 2 = 3–6 months (including 6 months), 3 = 6–12 months (including 12 months), 4)≥c12 months.